Most obesity drugs work by turning down appetite. A new experimental injection takes a different route: it tells fat cells to die. The drug, called CBL-514, was presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, and early results suggest it can shrink not only the fat you can pinch under the skin, but also the deep abdominal fat that wraps around your organs.

How does it work?

CBL-514 is a small-molecule injection designed to trigger apoptosis, the natural, orderly process by which a cell dismantles itself, in adipocytes (fat cells). According to its developer, Caliway Biopharmaceuticals in Taiwan, it leaves other cell types untouched. The idea is that fewer fat cells could mean less capacity to store fat in the first place.

Why visceral fat matters

Subcutaneous fat sits just under the skin. Visceral fat lies deep in the abdomen, around organs such as the liver and intestines. It is metabolically very active and is a major driver of insulin resistance, type 2 diabetes, and cardiovascular disease. That is why a treatment that reaches visceral fat is far more interesting medically than one that only changes how the waistline looks. Liposuction and abdominoplasty, for comparison, address only the subcutaneous layer.

What the human data show

The new analysis used MRI scans from a subgroup of two phase 2 trials (CBL-0204 and CBL-0205). Participants had a BMI between 22 and 30 and received abdominal injections of up to 600 mg of CBL-514 or placebo every three weeks, for up to 12 weeks. Forty people had follow-up data: 23 on the drug and 17 on placebo.

  • Four weeks after the last injection, visceral fat volume was on average 12.01% lower than baseline in the CBL-514 group, versus a 5.68% increase with placebo (a gap of 17.69 percentage points).
  • At the later follow-up (8 to 12 weeks after the last injection), the drug group was still 10.45% below baseline, while the placebo group had risen 11.76% (a gap of 22.21 percentage points).
  • In earlier phase 2 data on subcutaneous fat, 69.6% of treated participants lost at least 150 mL of fat volume at 8 weeks, compared with none on placebo.
  • Side effects were mostly mild to moderate, temporary injection-site reactions (pain, swelling, redness). No serious adverse events were reported.

The weight-regain idea: so far, only in rats

Many people regain weight after stopping GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, or Zepbound. In rats, adding CBL-514 to tirzepatide led to greater weight loss than tirzepatide alone, and the animals regained less weight after tirzepatide was stopped. The researchers hypothesize that with fewer fat cells, fat accumulates back more slowly. This has not been tested in humans, and the researchers themselves say it still needs to be proven.

Reasons for caution

  • No peer-reviewed paper yet. The results come from a late-breaking conference abstract. An independent expert quoted by the Science Media Centre noted that no full paper is available for this analysis.
  • Small sample, short follow-up. Forty people, followed for 8 to 12 weeks. A BMI range of 22 to 30 also spans normal weight up to the threshold of obesity, so this was not a group defined by obesity.
  • The placebo group gained visceral fat. This widens the gap between groups. The drug group’s own change was roughly a 10% reduction.
  • Links to the developer. According to the conflict-of-interest statement, Yu-Fang Ling, who is named in the press release as a co-analyst, is employed by and holds stock in Caliway, which makes the drug. Dr. W. Timothy Garvey, who presented the data, lists Caliway among the many companies whose advisory boards he has served on.
  • Open safety questions. Professor Justin Rochford of the University of Aberdeen pointed out that in rare diseases where healthy fat tissue is lost (lipodystrophies), fat shifts to organs such as the liver and can cause diabetes and heart disease. He said it will be important to show what CBL-514 does to liver fat, blood fats, and blood sugar control. Dr. Marie Spreckley of the University of Cambridge added that these results do not yet show that the treatment helps people lose weight or improves their health.

What comes next

Recruitment is under way for the first of two randomized, placebo-controlled phase 3 trials testing CBL-514 for non-surgical abdominal fat reduction, with first results expected at the end of 2027. Those trials, and longer follow-up that looks at liver fat and metabolic markers, will show whether the early signal holds up. Until then, CBL-514 is an interesting idea with promising but preliminary data.

Sources

  • Press release: European Association for the Study of Diabetes, “New weight-loss injection targets fat cells,” EurekAlert!, 1 October 2026: https://www.eurekalert.org/news-releases/1146063
  • Original research: Ling Y, Liang M, Garvey T, et al. CBL-514, a First-in-Class Adipocyte Apoptosis-Inducing Injection, Reduces MRI-Measured L2-L3 Visceral Adipose Tissue: Translational Evidence from Preclinical Models to a Phase 2 Clinical Trial. Late-breaking abstract LBA57, EASD Annual Meeting 2026, Milan. This is a conference abstract; no full peer-reviewed paper has been published.
  • Expert reaction: Science Media Centre, 1 October 2026: Expert reaction to conference abstract about CBL-514